Business● LowSep 23 · Sep 23, 2026, 3:03 PM
Compass Therapeutics downgraded at Wedbush as FDA seeks additional trial for lead asset
GlobeAlert Desk · curated from Seeking Alpha Tech · North America
Compass Therapeutics received a downgrade from Wedbush after the FDA requested an additional trial for its lead asset. This regulatory decision has implications for the company's product development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
1 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
North America theater · last 7 days
rising · 28 in the last 24h1,516
events logged
97
risk index / 100
Wildfires 600Attacks & Assaults 438Robberies & Theft 205Shootings 184Rocket Launches 38
- Cyber activity (155 reports)Cyber Threats · United States · 31m ago
- Conflict activity (127 reports)Conflict Events · United States · 48m ago
- Protest activity (111 reports)Protests · United States · 1h ago
More in Business
Business13m agoPorto in transformation: rehabilitation, mobility and futureObservador · PortugalBusiness14m agoBank of England expects inflation to continue rising until mid-next yearAsharq Al-Awsat [ar] · Saudi ArabiaBusiness14m agoHong Kong incinerator contractor sacks 9 workers, fines subcontractor HK$810,000South China Morning PostBusiness15m agoMercado Libre's Chief Financial Officer was chosen CFO of the yearLa Nación · Argentina